BioSpecifics Technologies Corp.
If you purchased BioSpecifics Technologies Corp. securities and would like to join the action, please click "Join This Action" below.
BIOSPECIFICS MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF BIOSPECIFICS TECHNOLOGIES CORP. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – BSTC
October 19, 2020.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of BioSpecifics Technologies Corp. (NASDAQ: BSTC) to Endo International plc for $88.50 per share is fair to BioSpecifics shareholders. On behalf of BioSpecifics shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
The BioSpecifics merger investigation concerns whether BioSpecifics and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for BioSpecifics shareholders; (2) determine whether the Endo is underpaying for BioSpecifics; and (3) disclose all material information necessary for BioSpecifics shareholders to adequately assess and value the merger consideration.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.